Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01367080
Other study ID # DWETR-I-1
Secondary ID
Status Completed
Phase Phase 1
First received June 2, 2011
Last updated August 6, 2014
Start date July 2011
Est. completion date September 2011

Study information

Verified date August 2014
Source Dong Wha Pharmaceutical Co. Ltd.
Contact n/a
Is FDA regulated No
Health authority Korea: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To evaluate the pharmacokinetics of single oral dose of Amitriptyline hydrochloride film-coated tablet 10mg & 25mg


Description:

Randomized, Single dose, 2-way crossover, Open Study to compare the pharmacokinetics profile of EtravilĀ®(Amitriptyline Hydrochloride) Tablet 10mg and EtravilĀ®(Amitriptyline Hydrochloride) Tablet 25mg after a single oral administration in healthy male volunteers


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date September 2011
Est. primary completion date August 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 50 Years
Eligibility Inclusion Criteria:

- a healthy adult male within the range of 19 to 50 years old at the time of screening

- one with weight of more than 55kg, in the range of IBW 20%

- Ideal Body Weight(IBW)(kg)={height(cm)-100}*0.9

- one who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol.

Exclusion Criteria:

- one with clinically significant disease in liver, kidney, nerve system, respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental disease or with medical history

- one with glaucoma

- one with disorders of micturition include benign prostatic hyperplasia

- one with gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug.

- one who is allergic or has clinically significant allergic history to the study drug, components or tricyclic antidepressants(TCA)

- one who shows the following result in vital sign: hypotension(systolic pressure = 100mmHg or diastolic pressure = 65mmHg) or hypertension(systolic pressure = 150mmHg or diastolic pressure = 95mmHg)

- one who has drug abuse history

- one who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before study drug administration, or who has taken any over-the-counter (OTC) drugs or vitamins (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)

- one who has participated in other clinical study within 2 months before study drug administration

- one who donated whole blood within 2 months or component blood within 1 month or who are donated within 1 month before the treatment

- one who drank Over 21 units/week of alcohol(1 unit = 10g of pure alcohol) or subjects who would not be able to stop drinking alcohol during the hospitalization

- one who are heavy smoker more than 10 cigarettes/day within 3 months prior to screening or subjects who would not be able to stop smoking during the hospitalization

- one who had a beverage containing caffeine, drank alcohol, or smoked within 48hrs before the hospitalization or who had a beverage containing grapefruits during the hospitalization

- one with clinically significant observations considered as unsuitable based on medical judgment by investigators

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
DWETR10
Amitriptyline hydrochloride 10mg(DWETR10) single dose
DWETR25
Amitriptyline hydrochloride 25mg(DWETR25) single dose

Locations

Country Name City State
Korea, Republic of Chonbuk National University Hospital. Jeonju-si Jeollabuk-do

Sponsors (2)

Lead Sponsor Collaborator
Dong Wha Pharmaceutical Co. Ltd. Chonbuk National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUClast and AUCinf Area Under the Plasma concentration-time curve from time Zero to Infinity(AUCinf) and Area Under the Plasma concentration-time curve from time Zero to last time(AUClast) of Amitryptiline in plasma Up to 72 hours No
Secondary Cmax Maximum Concentration(Cmax) of amitryptyline in plasma Up to 72 hours No
Secondary Tmax Time for Maximum Concentration(Tmax) of Amitryptyline in Plasma Up to 72 hours No
Secondary t1/2 Terminal half-time(t1/2) of Amitryptyline in Plasma Up to 72 hours No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A